EmeraMed Ltd is a biotechnology firm developing the lipophilic, blood-brain-barrier passing metal chelator and antioxidant Irminix®



The Product
Drug Name: Irminix®

International Non-Proprietary Name (INN): Emeramide

Molecule: N,N’-bis(2-mercaptoethyl)isophthalamide (NBMI)

Irminix® is a lipophilic, di-thiol metal chelator, and antioxidant. Orphan Drug Designation was received for the treatment of mercury toxicity in the EU and US in 2012. Pre-clinical safety studies, a Phase 1 trial, and a Phase 2a trial have been performed. The Company is working to obtain marketing authorization in the EU and the US for the treatment of mercury toxicity.


The Company
Information about the Company’s product development will be posted on this website as it becomes available. Our research and development efforts are committed to improving the health and well being of people and animals around the world by applying sound principles of medicine and science and working collaboratively with internationally renowned researchers and university centers.